Curis: FDA Lifts Partial Clinical Hold On TakeAim Lymphoma Study

(RTTNews) - Curis, Inc. (CRIS) announced the FDA has lifted the partial clinical hold on the TakeAim Lymphoma phase 1/2 study of emavusertib after reviewing the data package submitted by the company. As a result, the company updated its timeline for clinical data release to reflect the availability of updated preliminary data from this study in 2023. Also, the company is proactively discussing the clinical plans for emavusertib, including alignment on optimal dose and development path, with DHM2 for the TakeAim Lymphoma study.

"We are working with our clinical sites to quickly resume enrollment of new patients in this study in the third quarter," said James Dentzer, CEO.

For More Such Health News, visit rttnews.com.